The Zhitong Finance App learned that French trade unions organized workers at SNY.US (SNY.US) to go on strike starting Thursday to protest the company's intention to sell Opella, its consumer health division. The deal is worth about 16 billion US dollars. The strike was jointly initiated by the French Federation of Trade Unions (CGT) and the Confederation of French Steel Workers (CFDT) and is expected to cover the whole of France. Previously, Sanofi had begun negotiations with American private equity firm Clayton Dubilier & Rice to sell 50% of Opella's controlling interest. However, the deal has become a political issue due to concerns about potential layoffs and relinquishment of control over strategic assets, with the French government demanding guarantees that Doliprane's production remains in France, and has even proposed a possible stake in the sector. Sanofi said in a statement that the options under consideration will not reduce its industrial footprint in France, and emphasized that the future of its factories and employees in France is secure. The Barclays report indicates that regulatory concerns have had an impact on Sanofi's stock price, and the company will face pressure to announce a clear plan when announcing third-quarter results next week.

The Zhitong Finance App learned that French trade unions organized workers at SNY.US (SNY.US) to go on strike starting Thursday to protest the company's intention to sell Opella, its consumer health division. The deal is worth about 16 billion US dollars. The strike was jointly initiated by the French Federation of Trade Unions (CGT) and the Confederation of French Steel Workers (CFDT) and is expected to cover the whole of France. Previously, Sanofi had begun negotiations with American private equity firm Clayton Dubilier & Rice to sell 50% of Opella's controlling interest. However, the deal has become a political issue due to concerns about potential layoffs and relinquishment of control over strategic assets, with the French government demanding guarantees that Doliprane's production remains in France, and has even proposed a possible stake in the sector. Sanofi said in a statement that the options under consideration will not reduce its industrial footprint in France, and emphasized that the future of its factories and employees in France is secure. According to the Barclays report, the concerns of regulators have had an impact on Sanofi's stock price, and the company will face pressure to announce a clear plan when announcing third-quarter results next week.